Ozempic vs Wegovy: FDA Labels, Product Identity, and Cost Verification

Semaglutide is the shared ingredient, not the full identity

The cited FDA documents identify Ozempic and Wegovy as semaglutide injection, but they are separate branded product records. An accurate comparison starts with two rows: Ozempic injection under its cited prescribing information and Wegovy injection under its cited prescribing information. Ingredient sameness does not supply the brand, indication, pen design, labeled strength, package quantity, pharmacy route, benefit response, or transaction date needed for a complete evidence file.

Use the brand name whenever summarizing a label or commercial term. A note that says semaglutide price can accidentally combine an Ozempic pharmacy quote with a Wegovy plan response. Bind every fact to its brand, source ID, and check date. This guide does not compare outcomes, administration schedules, personal factors, or product rank.

Ozempic's cited FDA label lists three indication statements

The cited Ozempic label states that Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It also lists reduction of major adverse cardiovascular events—cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke—in adults with type 2 diabetes mellitus and established cardiovascular disease. The adult, type 2 diabetes, and established-disease qualifiers belong with the cardiovascular statement.

The third indication is reduction of the risk of sustained estimated-glomerular-filtration-rate decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease. The cited Ozempic label does not list chronic weight management. Preserve that boundary when describing FDA status. Do not replace the three exact uses with a broad diabetes-or-weight phrase, and do not borrow a Wegovy indication merely because both labels name semaglutide.

Wegovy's cited label covers distinct populations and purposes

The cited Wegovy label states that Wegovy is indicated with a reduced-calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular events—cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke—in adults with established cardiovascular disease and either obesity or overweight. Unlike the Ozempic cardiovascular statement, this population wording is not built around type 2 diabetes. Keep the brand and every population qualifier attached.

The same label includes reducing excess body weight and maintaining weight reduction long term in adults and pediatric patients age 12 or older with obesity, and in adults with overweight plus at least one weight-related comorbid condition. It also includes treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis, formerly called NASH, with moderate to advanced liver fibrosis consistent with stages F2 to F3 in adults. These are separate FDA statements, not performance comparisons.

The MASH indication carries an accelerated-approval qualifier

The Wegovy prescribing information says the noncirrhotic MASH indication was approved under accelerated approval based on improvement of MASH and fibrosis. It further states that continued approval may depend on verification and description of clinical benefit in a confirmatory trial. That regulatory qualifier is part of the exact status record. Omitting it would make the indication summary less precise than the cited label, even though this guide does not examine study results.

Record the label revision beside the MASH statement. The worksheet entry needs the brand, indication wording, adult population, noncirrhotic status, fibrosis range, accelerated-approval note, source, and check date. This is evidence maintenance, not clinical interpretation. The cited Ozempic label has no corresponding MASH indication, so that cell reads Not listed in the cited label.

Label indications support identity checks, not a broader verdict

Indication sections answer a narrow question: what use and population does this FDA label list for the named product? They help audit marketing language, organize plan questions, and prevent an ingredient from being described as though every brand carries the same FDA uses. The Ozempic and Wegovy statements differ in population and purpose, so a responsible summary preserves those differences without converting them into a choice or ranking.

This article intentionally excludes comparisons of clinical study results, administration instructions, and personal circumstances. It also gives no conclusion about any reader. Even apparently neutral shorthand can exceed the source: diabetes product, weight product, and heart product each omit qualifying text. Use the complete indication summary above, or quote the current prescribing information directly in an evidence packet, rather than relying on a slogan or search-result fragment.

The cited Ozempic injection label uses single-patient-use pens

The cited Ozempic label describes a clear, colorless injection in three prefilled, disposable, single-patient-use pen configurations. One configuration contains 2 mg/3 mL and delivers 0.25 mg or 0.5 mg per injection. Another contains 4 mg/3 mL and delivers 1 mg. The third contains 8 mg/3 mL and delivers 2 mg. These specifications identify package configurations; they are not a schedule or user instruction.

For transaction matching, capture total strength, total volume, delivered strength, pen count, and box count exactly as shown on the quote or package. Single-patient-use describes who the pen is assigned to; it should not be shortened to single-dose. If a pharmacy record merely says Ozempic pen, the exact configuration is Not stated. Obtain the product-specific detail before aligning the quote with a commercial offer that is limited by strength or fill definition.

The cited Wegovy injection label uses single-dose pens

The Wegovy label cited here describes prefilled single-dose pens in five presentations: 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL. The words single-dose distinguish this presentation identity from Ozempic's cited single-patient-use, multi-use pen configurations. That package distinction remains relevant even though both products are injections and both labels name semaglutide.

Create a distinct Wegovy identity key with brand, injection, single-dose pen, strength, volume, number of pens, supply period represented, and transaction channel. Do not copy Ozempic's pen volume, count, or fill definition into that row. The assigned Wegovy label supports the presentation fields, while the assigned source set supports no current Wegovy commercial amount. Product identity can therefore be complete even while price remains Not stated.

Bind every quote to label, package, and channel

A durable key for either product includes brand, active ingredient, cited label revision, dosage form, pen type, labeled strength, volume, package count, dispensing pharmacy, and purchase or insurance channel. Add the package's National Drug Code when the actual package or claim supplies it. The source record does not list those codes, so this article does not infer them. A blank code stays Not stated until an accepted transaction record fills it.

Use the key to reconcile the manufacturer page, plan formulary response, pharmacy quote, checkout summary, and receipt. If one record names only semaglutide, ask which branded product and package it concerns. If two records use different strengths or fill definitions, keep separate rows. Identity matching is more important than forcing a side-by-side number because a mathematically tidy comparison of unlike packages is commercially misleading.

Ozempic's 2026-07-23 cost page separates commercial lanes

The official Ozempic page checked 2026-07-23 displayed commercially covered, uninsured, and self-pay paths separately. For commercially insured people with Ozempic coverage, it said eligible users could pay as little as $25, subject to maximum savings of $100 per month. The page stated eligibility and restrictions, excluded government beneficiaries, defined one injection month as one box containing one Ozempic pen, and reserved program modification or cancellation rights.

That is not a universal $25 price. The floor depends on commercial insurance coverage, program eligibility, correct transaction processing, the monthly maximum, and current terms. The page described the offer as available for up to a three-month prescription and elsewhere stated up to 48 months. Retain both the per-month cap and duration language when recording it. A pharmacy's final processed amount, not the headline alone, completes the dated transaction record.

Ozempic self-pay figures require strength and time labels

For uninsured and self-pay injection transactions, the checked page listed a limited new-patient amount of $199 per month for the first two monthly fills at 0.25 mg or 0.5 mg through 2026-12-31. It then listed $349 per month for 0.25 mg, 0.5 mg, or 1 mg and $499 per month for 2 mg. Eligibility and restrictions apply, government beneficiaries are excluded, and Novo Nordisk may modify or cancel the program.

Keep introductory and standard figures in different worksheet rows. Label the $199 entry with new-patient status, first two fills, qualifying strengths, one-box fill definition, deadline, self-pay channel, and check date. Label $349 and $499 by strength and standard self-pay status. These are manufacturer-program terms, not list price, plan coverage, or a guaranteed pharmacy amount. Any separate service or fulfillment charge remains Not stated unless an accepted source itemizes it.

Current Wegovy price and coverage are Not stated here

The authorized set for this guide consists of the Ozempic FDA label, the Wegovy FDA label, and the official Ozempic cost page. No assigned source states a current Wegovy list price, cash amount, self-pay figure, commercial-savings term, or plan-coverage statistic. Publishing a remembered Wegovy number would break the source contract. The Wegovy commercial cells therefore read Not stated, and no cheapest-product conclusion is available from this article.

A later refresh needs an accepted first-party Wegovy source with the exact product form, strength, package, fill definition, channel, insurance category, eligibility, cap, duration, deadline, change rights, and check date. Until then, do not compare Ozempic's $25 floor or $199 introductory amount with an unlabeled Wegovy value from a snippet or coupon site. Missing evidence means the comparison is incomplete; it does not mean Wegovy lacks an offer or coverage.

Coverage verification starts with the exact brand and claim lane

The official Ozempic cost page says coverage depends on the individual plan's formulary and applicable prior-authorization or step-therapy requirements and should be confirmed with the insurer. Ask about the exact Ozempic injection configuration, the plan year, pharmacy network, deductible position, cost-sharing rule, administrative criteria, and response effective date. A manufacturer savings card is not the same record as the plan's coverage determination.

Use the same brand-specific method for Wegovy, but do not imply a plan result from Ozempic's page or from the shared ingredient. Request the formulary record and current plan response for Wegovy itself. Record covered, noncovered, criteria apply, or Not stated only when the source supports that entry. Save the inquiry date and reference number if provided. Coverage can change independently from FDA labeling and independently between products that contain semaglutide.

Build a comparison table that keeps unknowns visible

Use separate Ozempic and Wegovy columns with rows for active ingredient, indication statements, label revision, injection form, pen type, strength, volume, package count, pharmacy, plan, channel, list price, cash quote, insured amount, savings cap, self-pay amount, introductory and standard periods, deadline, and source date. Enter Not stated whenever accepted evidence does not answer a row.

Add a document column showing whether the value came from the FDA label, manufacturer terms, insurer response, pharmacy quote, checkout, or receipt. FDA labels control the identity and indication statements used here; they do not establish the household price. Commercial pages supply conditional offer terms; they do not replace a plan response. This source separation makes updates easier because a changed offer can be refreshed without rewriting the FDA identity record.

Frequent comparison errors come from collapsing categories

One error is calling both products semaglutide pens and dropping whether the device is Ozempic single-patient-use or Wegovy single-dose. Another is assigning Wegovy's weight-reduction label to Ozempic, or Ozempic's type 2 diabetes indications to Wegovy. A third is comparing Ozempic's introductory self-pay amount with another product's list price. Each mistake joins fields that the sources keep separate and creates a claim the frozen evidence does not support.

Other errors include omitting a program cap, calling a savings floor insurance coverage, using an offer after its deadline, treating one processed fill as a permanent amount, or filling Wegovy's missing price with stale third-party content. Keep every dollar tied to brand, strength, fill, channel, insurance category, term, and date. If those fields cannot be aligned, report an incomplete comparison instead of a price winner.

Evidence scope, authorship, and held status

The evidence map uses two FDA labels for brand-specific indication and presentation statements and one first-party Ozempic page for dated commercial terms. All were recorded in the source record with a 2026-07-23 check. Source locations remain in structured source objects, not the narrative. No assigned source supports current Wegovy pricing, so the guide preserves that absence.

Izaiah Tilton is the Publisher and only named author. No clinical reviewer or clinical credential is claimed. The page is noindex, non-promotional, non-monetized, and under editorial review, with no active manufacturer or affiliate link. Recheck current labels, accepted manufacturer terms, the exact plan, and the pharmacy quote. This document guarantees no price, coverage, eligibility, availability, reimbursement, or savings.

Sources

1. U.S. Food and Drug Administration · supports ozempic-wegovy-shared-ingredient-distinct-products, ozempic-exact-indications, ozempic-injection-presentations · checked 2026-07-23
2. U.S. Food and Drug Administration · supports ozempic-wegovy-shared-ingredient-distinct-products, wegovy-exact-indications, wegovy-injection-presentations · checked 2026-07-23
3. Novo Nordisk / Ozempic · supports ozempic-cost-20260723, ozempic-coverage-verification · checked 2026-07-23

Next step

The cited Ozempic and Wegovy labels both name semaglutide injection, yet they establish separate brands, indication statements, and pen configurations. Ozempic's cited uses are tied to adults with type 2 diabetes; Wegovy's cited uses cover specified cardiovascular, long-term weight-reduction, and MASH populations. For commercial comparison, preserve product, form, strength, package, channel, insurance category, offer duration, cap, and check date. The 2026-07-23 Ozempic cost source supports qualified figures; this article's authorized set does not state a current Wegovy price. Keep that cell Not stated until an accepted first-party Wegovy source is added.